drug
zonisamide
Marketedupdated 3mo agoby Granules Pharma LLC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying zonisamide
- phase4Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures
- phase2Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)
- phase3The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
- phase2Noise-Induced Hearing Loss-Acute Exposure Treatment
- phase1Fasting Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg
- phase1Fed Study of Zonisamide Capsules 100 mg and Zonegran® Capsules 100 mg
- —A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 18, 2038
~12.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Aug 18, 2038method-of-use (U-3458)US 11478456
- Aug 18, 2038formulationUS 11529333
- Aug 18, 2038formulationUS 12491179
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that